Preliminary test of anhedonia scale in depression and cannabis use

Psychometric Evaluation of the Dimensional Anhedonia Rating Scale (DARS): A Preliminary Study.

The Journal of nervous and mental disease β€’ β€’ Relevant
πŸ€–

AI Summary

This preliminary human psychometric study asked whether the Dimensional Anhedonia Rating Scale (DARS) can reliably measure reduced ability to experience pleasure in people with co-occurring major depressive disorder (MDD) and cannabis use disorder (CUD). Thirty-five participants completed the DARS alongside established measures of anhedonia, depression, and anxiety. No cannabis or other treatment intervention was tested; the study evaluated questionnaires and their relationships with one another.

The DARS showed a supported four-factor structure, excellent internal consistency, and expected agreement with the Snaith-Hamilton Pleasure Scale (SHAPS), including a reported correlation of ρ = βˆ’.64. It also showed good ability to distinguish participants classified as having anhedonia by the SHAPS, with AUC = .81; the study-derived threshold of 65 had approximately .85 sensitivity and .75 specificity. These findings provide preliminary support for using the DARS in this clinical population, but the small sample and preliminary design mean the study cannot establish causation, treatment benefit, or how well the scale generalizes beyond people with both MDD and CUD. This is an abstract-based summary, not a review of the full text.

πŸ’‘ Key Findings

1
In 35 people with co-occurring MDD and CUD, the DARS supported a four-factor structure and demonstrated excellent internal consistency.
Good
65%
2
The DARS showed expected convergent validity with the SHAPS, including a reported correlation of ρ = βˆ’.64.
Good
70%
3
The DARS demonstrated good discrimination for SHAPS-defined anhedonia, with AUC = .81, and a study-derived threshold showing approximately .85 sensitivity and .75 specificity.
Good
70%
4
The findings provide preliminary evidence of the DARS’s utility in people with co-occurring MDD and CUD, but do not establish cannabis-related causation or treatment effects.
High
85%

πŸ“„ Original Abstract

AIM: Anhedonia is a transdiagnostic symptom of major depressive disorder (MDD) that is also influenced by substance use, yet the Dimensional Anhedonia Rating Scale (DARS) has only been validated in MDD. This study examined the psychometric properties of the DARS in co-occurring MDD and cannabis use disorder (CUD). METHODS: Thirty-five participants completed the DARS, Snaith-Hamilton Pleasure Scale (SHAPS), Hamilton Rating Scale for Depression (HRSD), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Analyses included confirmatory factor analysis, internal consistency, Spearman correlations, group comparisons, and ROC analysis against SHAPS-defined anhedonia. RESULTS: The DARS supported a four-factor (and second-order) structure, demonstrated excellent internal consistency, and showed expected convergent validity (e.g., SHAPS ρ=-.64). ROC analysis indicated good discrimination (AUC=.81) with a Youden-derived threshold of 65 (sensitivity β‰ˆ.85; specificity β‰ˆ.75). CONCLUSIONS: This study provides preliminary evidence of the utility of the DARS in co-occurring MDD and CUD.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.